HTA plays a crucial role in informing decision-making on the reimbursement of medical technologies globally. It is a multidisciplinary activity which studies the clinical and the cost effectiveness of new pharmaceuticals or any other medical interventions, as well as how health policy might be impacted by the new technology and what the social and ethical implications might be for patients and the wider society.
Our current Health Technology Regulation & Assessment research projects:
Impact-HTA: Improved methods and actionable tools for enhancing HTA
ESMO – Multi-criteria value framework for cancer products